<p>Enliven Therapeutics, Inc. (NASDAQ:ELVN - 获取免费报告) 的股价在周四下跌了 6.5%，原因是公司内部人士出售了股票。该公司股价最低曾达到 19.36 美元，最后交易价格为 18.8590 美元。在午盘交易中，约有 54,409 股成交，较平均每日成交量 430,945 股下降了 87%。该股票之前的收盘价为 20.17 美元。</p>
<p>获取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
<p>具体来说，首席运营官 Anish Patel 在 12 月 8 日星期一的交易中出售了 6,663 股公司的股票。股票以平均价格 21.02 美元出售，总价值为 140,056.26 美元。出售后，首席运营官直接持有 263,311 股公司的股票，价值约为 5,534,797.22 美元。此次交易使其持股减少了 2.47%。该出售在向 SEC 的法律文件中披露，相关文件可通过此链接访问。</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司最近对 ELVN 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Enliven Therapeutics 股票的 “卖出（d-）” 评级。Wall Street Zen 在 11 月 15 日的研究报告中将 Enliven Therapeutics 的股票评级从 “卖出” 上调至 “持有”。五位分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 41.20 美元。</p>
<p><strong>获取我们对 Enliven Therapeutics 的最新股票分析</strong></p>
<h2>Enliven Therapeutics 股价下跌 6.1%</h2>
<p>该股票的 50 日简单移动平均线为 20.86 美元，200 日简单移动平均线为 20.43 美元。该公司的市值为 11.2 亿美元，市盈率为-10.17，贝塔值为 0.35。</p>
<p>Enliven Therapeutics (NASDAQ:ELVN - 获取免费报告) 最近于 11 月 13 日发布了季度财报。公司报告本季度每股收益为（0.32 美元），超出分析师的共识预期（0.43 美元）0.11 美元。整体来看，卖方分析师预测 Enliven Therapeutics, Inc.在当前财年的每股收益将为-1.95。</p>
<h2>机构资金流入和流出</h2>
<p>对冲基金最近对该公司的持仓进行了调整。Vestal Point Capital LP 在第三季度将其在 Enliven Therapeutics 的持仓增加了 364.0%。Vestal Point Capital LP 现在持有 1,160,000 股公司股票，价值 23,745,000 美元，此前在上个季度又购买了 910,000 股。TCG Crossover Management LLC 在第二季度购买了 Enliven Therapeutics 的新头寸，价值约为 9,990,000 美元。Duquesne Family Office LLC 在第三季度将其在 Enliven Therapeutics 的持仓增加了 104.6%。Duquesne Family Office LLC 现在持有 947,405 股公司股票，价值 19,393,000 美元，此前在上个季度又收购了 484,405 股。Candriam S.C.A.在第二季度购买了 Enliven Therapeutics 的新股份，价值约为 8,358,000 美元。最后，Franklin Resources Inc.在第二季度将其在 Enliven Therapeutics 的持仓增加了 2,029.3%。Franklin Resources Inc.现在持有 430,240 股公司股票，价值 8,631,000 美元，此前在上个季度又购买了 410,034 股。当前 95.08% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Enliven Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Enliven Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于小分子抑制剂的发现和开发，以帮助癌症患者。公司的主要产品候选包括 ELVN-001，该药物正在对慢性髓性白血病成人进行的 1 期临床试验中评估；以及 ELVN-002，该药物正在对具有 HER2 改变的成人实体瘤进行的 1 期临床试验中评估。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Enliven Therapeutics 更好</li>
<li>什么是股息？购买最佳股息股票</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告可能会出现痛苦的反转</li>
<li>技术股解析：关于科技你需要知道的事情</li>
<li>错过了 NVIDIA？Braze 可能是下一个 AI 股票突破</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>沃尔玛的纳斯达克转换可能会改变 WMT 股票的一切</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Enliven Therapeutics 吗？</h2>
<p>在考虑 Enliven Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Enliven Therapeutics 并不在名单上。</p>
<p>虽然 Enliven Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ELVN

<p>Enliven Therapeutics (NASDAQ:ELVN) 的股价在首席运营官 Anish Patel 出售 6,663 股后下跌了 6.5%。该股票交易最低价为 19.36 美元，交易量显著下降。尽管出现下滑，分析师仍维持 “适度买入” 评级，目标价为 41.20 美元。机构投资者正在调整其持仓，对冲基金有显著的资金流入。Enliven 专注于开发用于癌症治疗的小分子抑制剂，关键产品正在临床试验中</p>

<p>Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price dropped 6.5% on Thursday after an insider sold shares in the company. The company traded as low as $19.36 and last traded at $18.8590. Approximately 54,409 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 430,945 shares. The stock had previously closed at $20.17.</p>
<div class="lb-trans"><p>Enliven Therapeutics, Inc. (NASDAQ:ELVN - 获取免费报告) 的股价在周四下跌了 6.5%，原因是公司内部人士出售了股票。该公司股价最低曾达到 19.36 美元，最后交易价格为 18.8590 美元。在午盘交易中，约有 54,409 股成交，较平均每日成交量 430,945 股下降了 87%。该股票之前的收盘价为 20.17 美元。</p>
</div><p>Get <strong>Enliven Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
</div><p>Specifically, COO Anish Patel sold 6,663 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $21.02, for a total value of $140,056.26. Following the sale, the chief operating officer directly owned 263,311 shares in the company, valued at approximately $5,534,797.22. The trade was a 2.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.</p>
<div class="lb-trans"><p>具体来说，首席运营官 Anish Patel 在 12 月 8 日星期一的交易中出售了 6,663 股公司的股票。股票以平均价格 21.02 美元出售，总价值为 140,056.26 美元。出售后，首席运营官直接持有 263,311 股公司的股票，价值约为 5,534,797.22 美元。此次交易使其持股减少了 2.47%。该出售在向 SEC 的法律文件中披露，相关文件可通过此链接访问。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms have recently issued reports on ELVN. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Enliven Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $41.20.</p>
<div class="lb-trans"><p>几家研究公司最近对 ELVN 发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Enliven Therapeutics 股票的 “卖出（d-）” 评级。Wall Street Zen 在 11 月 15 日的研究报告中将 Enliven Therapeutics 的股票评级从 “卖出” 上调至 “持有”。五位分析师对该股票给予了买入评级，一位分析师则给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 41.20 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Enliven Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Enliven Therapeutics 的最新股票分析</strong></p>
</div><h2>Enliven Therapeutics Trading Down 6.1%</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 股价下跌 6.1%</h2>
</div><p>The stock has a fifty day simple moving average of $20.86 and a two-hundred day simple moving average of $20.43. The firm has a market cap of $1.12 billion, a PE ratio of -10.17 and a beta of 0.35.</p>
<div class="lb-trans"><p>该股票的 50 日简单移动平均线为 20.86 美元，200 日简单移动平均线为 20.43 美元。该公司的市值为 11.2 亿美元，市盈率为-10.17，贝塔值为 0.35。</p>
</div><p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.11. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Enliven Therapeutics (NASDAQ:ELVN - 获取免费报告) 最近于 11 月 13 日发布了季度财报。公司报告本季度每股收益为（0.32 美元），超出分析师的共识预期（0.43 美元）0.11 美元。整体来看，卖方分析师预测 Enliven Therapeutics, Inc.在当前财年的每股收益将为-1.95。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP raised its position in shares of Enliven Therapeutics by 364.0% in the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company's stock worth $23,745,000 after buying an additional 910,000 shares in the last quarter. TCG Crossover Management LLC bought a new position in Enliven Therapeutics in the 2nd quarter worth about $9,990,000. Duquesne Family Office LLC raised its holdings in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company's stock valued at $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Candriam S.C.A. bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $8,358,000. Finally, Franklin Resources Inc. grew its holdings in shares of Enliven Therapeutics by 2,029.3% during the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company's stock worth $8,631,000 after purchasing an additional 410,034 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。Vestal Point Capital LP 在第三季度将其在 Enliven Therapeutics 的持仓增加了 364.0%。Vestal Point Capital LP 现在持有 1,160,000 股公司股票，价值 23,745,000 美元，此前在上个季度又购买了 910,000 股。TCG Crossover Management LLC 在第二季度购买了 Enliven Therapeutics 的新头寸，价值约为 9,990,000 美元。Duquesne Family Office LLC 在第三季度将其在 Enliven Therapeutics 的持仓增加了 104.6%。Duquesne Family Office LLC 现在持有 947,405 股公司股票，价值 19,393,000 美元，此前在上个季度又收购了 484,405 股。Candriam S.C.A.在第二季度购买了 Enliven Therapeutics 的新股份，价值约为 8,358,000 美元。最后，Franklin Resources Inc.在第二季度将其在 Enliven Therapeutics 的持仓增加了 2,029.3%。Franklin Resources Inc.现在持有 430,240 股公司股票，价值 8,631,000 美元，此前在上个季度又购买了 410,034 股。当前 95.08% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Enliven Therapeutics</h2>
<div class="lb-trans"><h2>关于 Enliven Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.</p>
<div class="lb-trans"><p>Enliven Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于小分子抑制剂的发现和开发，以帮助癌症患者。公司的主要产品候选包括 ELVN-001，该药物正在对慢性髓性白血病成人进行的 1 期临床试验中评估；以及 ELVN-002，该药物正在对具有 HER2 改变的成人实体瘤进行的 1 期临床试验中评估。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Enliven Therapeutics</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Missed NVIDIA? Braze Might Be the Next AI Stock Breakout</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Walmart’s NASDAQ Switch Could Change Everything for WMT Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Enliven Therapeutics 更好</li>
<li>什么是股息？购买最佳股息股票</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告可能会出现痛苦的反转</li>
<li>技术股解析：关于科技你需要知道的事情</li>
<li>错过了 NVIDIA？Braze 可能是下一个 AI 股票突破</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>沃尔玛的纳斯达克转换可能会改变 WMT 股票的一切</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enliven Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Enliven Therapeutics 吗？</h2>
</div><p>Before you consider Enliven Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Enliven Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Enliven Therapeutics 并不在名单上。</p>
</div><p>While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enliven Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Enliven Therapeutics (NASDAQ:ELVN) 股价下跌 6.5%，因内部人士出售股票